Browsing by Author "Wilder, Julius"

Now showing 1 - 6 of 6
  • Thumbnail Image
    ItemOpen Access
    A Review of the Natural History of Chronic Hepatitis C Infection
    (North American Journal of Medicine and Science, 2014) Wilder, Julius; Patel, Keyur
  • Thumbnail Image
    ItemOpen Access
    A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment.
    (J Natl Med Assoc, 2016-02) Wilder, Julius; Saraswathula, Anirudh; Hasselblad, Vic; Muir, Andrew
    The African American/Black population in the United States (US) is disproportionately affected by hepatitis C virus (HCV) and has lower response rates to current treatments. This analysis evaluates the participation of African American/Blacks in North American and European HCV clinical trials. The data source for this analysis was the PubMed database. Randomized controlled clinical trials (RCT) on HCV treatment with interferon 2a or 2b between January 2000 and December 2011 were reviewed. Inclusion criteria included English language and participants 18 years or older with chronic HCV. Exclusion criteria included non-randomized trials, case reports, cohort studies, ethnic specific studies, or studies not using interferon-alfa or PEG-interferon. Of the 588 trials identified, 314 (53.4%) fit inclusion criteria. The main outcome was the rate of African American/ Black participation in North American HCV clinical trials. A meta-analysis comparing the expected and observed rates was performed. Of the RCT's that met search criteria, 123 (39.2%) reported race. Clinical trials in North America were more likely to report racial data than European trials. Racial reporting increased over time. There was a statistically significant difference among the expected and observed participation of African Americans in HCV clinical trials in North America based on the prevalence of this disease within the population. The burden of HCV among African Americans in North America is not reflected in those clinical trials designed to treat HCV. Research on minority participation in clinical trials and how to increase minority participation in clinical trials is needed.
  • Thumbnail Image
    ItemOpen Access
    Acute liver failure in the setting of herpes simplex virus and coexistent acute fatty liver of pregnancy
    (Case Reports in Clinical Pathology, 2014-12-03) Wilder, Julius; Chang, Sydney; Cardona, Diana; Patel, Keyur; Brady, Carla
  • Thumbnail Image
    ItemOpen Access

    Acute Intermittent Porphyria: Current Perspectives And Case Presentation

    (Therapeutics and Clinical Risk Management) Spiritos, Zachary; Salvador, Shakirat; Mosquera, Diana; Wilder, Julius
  • Thumbnail Image
    ItemOpen Access
    Racial disparities in liver cancer: Evidence for a role of environmental contaminants and the epigenome.
    (Frontiers in oncology, 2022-01) Vidal, Adriana C; Moylan, Cynthia A; Wilder, Julius; Grant, Delores J; Murphy, Susan K; Hoyo, Cathrine
    Liver cancer incidence has tripled since the early 1980s, making this disease one of the fastest rising types of cancer and the third leading cause of cancer-related deaths worldwide. In the US, incidence varies by geographic location and race, with the highest incidence in the southwestern and southeastern states and among racial minorities such as Hispanic and Black individuals. Prognosis is also poorer among these populations. The observed ethnic disparities do not fully reflect differences in the prevalence of risk factors, e.g., for cirrhosis that may progress to liver cancer or from genetic predisposition. Likely substantial contributors to risk are environmental factors, including chemical and non-chemical stressors; yet, the paucity of mechanistic insights impedes prevention efforts. Here, we review the current literature and evaluate challenges to reducing liver cancer disparities. We also discuss the hypothesis that epigenetic mediators may provide biomarkers for early detection to support interventions that reduce disparities.
  • Thumbnail Image
    ItemOpen Access
    The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease.
    (Med Devices (Auckl), 2014) Wilder, Julius; Patel, Keyur
    An important aspect of managing chronic liver disease is assessing for evidence of fibrosis. Historically, this has been accomplished using liver biopsy, which is an invasive procedure associated with risk for complications and significant sampling and observer error, limiting the accuracy for determination of fibrosis stage. Hence, several serum biomarkers and imaging methods for noninvasive assessment of liver fibrosis have been developed. In this article, we review the current literature on an important noninvasive imaging modality to measure tissue elastography (FibroScan(®)). This ultrasound-based technique is now increasingly available in many countries and has been shown to be a reliable and safe noninvasive means of assessing disease severity in chronic liver disease of varying etiology.